Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

May 31, 2010

Conditions
HIV InfectionsHepatitis B
Interventions
DRUG

Entecavir with continued standard of care antiretroviral therapy

1 mg by mouth daily

DRUG

continued standard of care with tenofovir in addition to emtricitabine or lamivudine

continued standard of care with tenofovir in addition to emtricitabine or lamivudine

Trial Locations (1)

94110

San Francisco General HIV Clinical Trials Group, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT00662545 - Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection | Biotech Hunter | Biotech Hunter